Raymond E. Cabillot Sells 5,381 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,381 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total value of $224,064.84. Following the completion of the transaction, the director now owns 319,752 shares of the company’s stock, valued at approximately $13,314,473.28. The trade was a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Pro-Dex Stock Performance

NASDAQ PDEX opened at $42.95 on Friday. The firm has a market capitalization of $140.02 million, a P/E ratio of 27.89 and a beta of 0.56. The stock has a 50-day simple moving average of $47.59 and a two-hundred day simple moving average of $34.34. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $59.60.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 16.74% and a net margin of 9.17%. On average, equities analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PDEX shares. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets upped their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Hedge Funds Weigh In On Pro-Dex

Several large investors have recently made changes to their positions in the company. FMR LLC increased its holdings in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares during the period. Bard Associates Inc. grew its position in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares during the period. Ritholtz Wealth Management purchased a new position in shares of Pro-Dex in the 4th quarter valued at about $572,000. Finally, JPMorgan Chase & Co. raised its holdings in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after purchasing an additional 529 shares during the period. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.